Current Status: Site-Specific Antibody Drug Conjugates

Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals, combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs on the market, a plethora of novel ADC technologies has emerged, covering as div...

Descripción completa

Detalles Bibliográficos
Autores principales: Schumacher, Dominik, Hackenberger, Christian P. R., Leonhardt, Heinrich, Helma, Jonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891387/
https://www.ncbi.nlm.nih.gov/pubmed/27003914
http://dx.doi.org/10.1007/s10875-016-0265-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891387/
https://www.ncbi.nlm.nih.gov/pubmed/27003914
http://dx.doi.org/10.1007/s10875-016-0265-6

Ejemplares similares